Homburg

• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 High-grade B-cell lymphoma (HGBL)
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants … Recruiting
  2024-519152-82-00 5 2025-09-03 Relapsed/Refractory Follicular Lymphoma
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima … Recruiting
  2024-518893-15-00 5 2025-07-29 Chronic lymphotic leukemia and Small Lymphocytic lymphoma
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction Recruiting
  2024-519219-32-00 5 2025-06-23 Heart Failure With Reduced Ejection Fraction
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge … Recruiting
  2023-509547-27-00 5 2025-05-22 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• A Basket Study of Vosoritide in Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome with I … Recruiting
  2024-515861-33-00 4 2025-03-25 Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, an
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni … Recruiting
  2023-510292-65-00 5 2025-02-25 chronic graft-versus-host disease
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-514281-39-00 5 2025-02-14 Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR … Recruiting
  2023-510109-16-00 4 2025-01-06 Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other I
• Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting
  2023-504925-38-00 4 2024-12-10 patients with hormone receptor (HR)-positive, HER2-negative locally ad
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensate … Recruiting
  2024-512895-36-00 5 2024-11-25 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- … Recruiting
  2023-509292-17-00 4 2024-11-08 primary high-risk lobular breast cancer
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron … Recruiting
  2023-508338-33-00 5 2024-10-01 Chronic Inflammatory Demyelinating Polyneuropathy
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma

Showing 49–72 of 180 trials